REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
다가오는 임상 시험
-
Magnus MedicalCongressionally Directed Medical Research Programs모병
-
Nicholas ButowskiSiren Biotechnology아직 모집하지 않음신경교종 | 뇌종양 | 재발성 고등급 신경교종미국
-
State University of New York at Buffalo아직 모집하지 않음
-
Poitiers University Hospital아직 모집하지 않음
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음
-
University of California, Irvine모병뇌암 | CNS 암 | 신경계 암 | 뇌전이암미국
-
Guangdong Raynovent Biotech Co., Ltd아직 모집하지 않음
-
The Hong Kong Polytechnic UniversityWu Jieh Yee Charitable Foundation모병
-
Shanghai General Hospital, Shanghai Jiao Tong University...아직 모집하지 않음
-
Sun Yat-sen University아직 모집하지 않음금연 | AI 에이전트 | Early-Stage Cancer
-
Affiliated Hospital of Nantong University아직 모집하지 않음